Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : TSB Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients developed in collaboration with the 3rd People’s Hospital of Shenzhen and Tsinghua University.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : TSB Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PTX-COVID-19-B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Details : Everest’s licensing partner Providence is currently evaluating PTX-COVID19-B in a head-to-head clinical trial against Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. Everest and Providence also plan to initiate a trial in 2022 to further expand the ind...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 04, 2022
Lead Product(s) : PTX-COVID-19-B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Ligand Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Ligand has preclinical data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous co...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 21, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Ligand Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Irbesartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China Resources Double Crane Irbesartan Dispersible Tablet Passes Evaluation
Details : Irbesartan is an angiotensin II receptor blocker, small molecule drug candidate, which is indicated for the treatment of hypertension and diabetic nephropathy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2021
Lead Product(s) : Irbesartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
